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ABSTRACT
The objectives of this analysis are to re-examine the foundational studies of the in vivo metabolism
of plasma LDL (low-density lipoprotein) particles in humans and, based on them, to reconstruct
our understanding of the governance of the concentration of plasma LDL and the maintenance
of cholesterol homoeostasis in the hepatocyte. We believe that regulation of cholesterol
homoeostasis within the hepatocyte is demonstrably more complex than envisioned by the LDL
receptor paradigm, the conventional model to explain the regulation of plasma LDL and the ﬂuxes
of cholesterol into the liver, a model which was generated in the ﬁbroblast but has never been fully
validated in the hepatocyte. We suggest that the LDL receptor paradigm should be reconﬁgured
as the apoB (apolipoprotein B) paradigm, which states that the rate at which LDL particles are
produced is at least an important determinant of their concentration in plasma as the rate at which
they are cleared from plasma and that secretion of cholesterol within VLDL (very-low-density
lipoprotein) particles is an important mechanism of maintaining cholesterol homoeostasis within
the hepatocyte. These two paradigms are not mutually exclusive. The LDL receptor paradigm,
however, includes only one critical aspect of the regulation of plasma LDL, namely the rate at
which LDL particles are cleared through the LDL receptor pathway, but ignores another – the
rate at which LDL particles are added to the plasma compartment. The apoB paradigm includes
both and points to a different model of how the hepatocyte achieves cholesterol homoeostasis in
a complex metabolic environment.
INTRODUCTION
Few ideas deﬁne their time. The LDL (low-density
lipoprotein) receptor paradigm certainly achieved that
rare rank. The LDL receptor paradigm states that the
LDL pathway, the normal route by which LDL particles
are removed by plasma, is the principal determinant of
the concentration of LDL in plasma and therefore the
principal determinant of the risk of coronary disease
attributable to LDL [1]. Furthermore, the activity of the
LDL pathway, and therefore the concentration of LDL
inplasma,isgovernedbytheconcentrationofcholesterol
within a key intracellular regulatory pool. Increased
delivery of cholesterol to the cell via the LDL pathway
results in the down-regulation of both the synthesis of
cholesterol and the synthesis of LDL receptors, whereas
reduced delivery of cholesterol results in up-regulation
of the synthesis of cholesterol and LDL receptors. The
LDL receptor paradigm was developed in ﬁbroblasts and
represents a simple action–reaction homoeostatic model
whose single objective is to limit the mass of cholesterol
entering the cell. However, not only does the ﬁbroblast
not play a signiﬁcant role in total body cholesterol,
but also the studies were conducted under experimental
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conditions which did not allow physiological egress of
cholesterol from the ﬁbroblast.
Whenitcomestothehepatocyte,whichisatthecentre
of all the major cholesterol ﬂuxes within the organism,
the LDL receptor paradigm is accurate but incomplete.
The apoB (apolipoprotein B) paradigm extends our
understandingoftheregulationofplasmaLDLbytaking
production as well as clearance of apoB particles into
account. The arguments advanced in this article represent
novel extensions of previous critiques of the LDL
receptor paradigm [2–6] that coalesce with the
formulation of the apoB paradigm and our hypothesis
as to cholesterol homoeostasis within the hepatocyte.
In brief, we hypothesize that most of the cholesterol
that enters the hepatocyte as part of an LDL particle
is secreted from it as part of a VLDL (very low-density
lipoprotein)particlewithoutcomingintofullequilibrium
withtheexchangeableandregulatorypoolsofcholesterol
within the hepatocyte. Consequently, cholesterol and
LDL receptor synthesis will not be down-regulated. By
contrast, cholesterol that enters the hepatocyte directly
or within chylomicron remnant particles will enter the
exchangeable and regulatory pools of cholesterol before
it can be esteriﬁed and secreted from the cell. As such,
cholesterol and LDL receptor synthesis will be down-
regulated. Therefore the physiological responses of the
hepatocyte are governed to an important degree by the
route by which cholesterol gains access to the hepatocyte
and these responses are important determinants of the
regulation of atherogenic particle number in plasma.
DETERMINANTS OF PLASMA LDL PARTICLE
NUMBER: LDL-apoB
LDL is a cholesterol-rich lipoprotein particle generated
as the end product of the metabolism of VLDL,
the triacylglycerol (triglyceride)-rich lipoprotein particle
secreted by the liver. For the purposes of this discussion,
we will not deal with the fact that both VLDL and
LDL particles are heterogeneous in composition, that is,
each is present in plasma in multiple forms, some larger
containing more core lipid and others smaller containing
less.EachVLDLandLDLparticlecontainsonemolecule
of apoB. Therefore VLDL-apoB equals the number of
VLDL particles and LDL-apoB equals the number
of LDL particles.
The concentration of LDL particles in plasma, the
concentration of LDL-apoB, is determined by the rate
at which they are produced and by the rate at which
they are cleared from plasma. At steady state, that is,
when the concentration of LDL is constant day-to-day,
the number of LDL particles produced per day must
equal the number cleared per day. Similarly, the mass
of cholesterol that enters the LDL density range per day
must equal the mass of cholesterol that is cleared in LDL
particles per day. Since more than 90% of the removal
of LDL takes place in the liver, the liver determines
the rates of LDL clearance from plasma. The space of
Disse presents no barrier to the movement of plasma
lipoproteins from the vascular space to the extravascular
space; accordingly, the concentration of LDL outside the
hepatocyte is equal to the intravascular concentration of
LDL.
LDL particles are irreversibly cleared from plasma
either by the LDL receptor pathway or by non-
speciﬁc pathways. Extensive reviews of the LDL
receptorpathwayareavailable[7,8].Thisanalysisfocuses
on the kinetic properties of the clearance pathways
and the key points are: the binding of a LDL particle
to its speciﬁc receptor is high-afﬁnity, but the absolute
transport capacity of the LDL pathway is limited. Once
the LDL pathway is saturated, the number of LDL
particles cleared cannot increase. Even so, the activity of
theLDLpathwaywillnotautomaticallybereduced.That
will not occur unless the mass of cholesterol within the
regulatory pool of cell cholesterol increases, triggering
the cascade of metabolic events that results in diminished
synthesis of LDL receptors and cholesterol. Unless this
occurs, trafﬁc will continue through the LDL receptor
pathway at the maximal rate possible.
Non-speciﬁc pathways make up the second route
of removal of LDL particles from plasma. They are
low-afﬁnity, but non-saturable [7,9]. Accordingly, as the
plasma LDL increases, sodoes the mass of LDL removed
by the non-speciﬁc pathways. Thus the two pathways
differ in which characteristic is constant: the non-speciﬁc
pathways remove a constant fraction of the total number
of LDL particles in the plasma pool, whereas the LDL
receptor pathway, once saturated, removes a constant
number of LDL particles from the plasma pool. By
contrast, at higher and higher concentrations of LDL, the
non-speciﬁc pathways take up more and more LDL
particles [9,10].
RELATIONSHIP BETWEEN LDL RECEPTORS,
LDL CLEARANCE AND PLASMA LDL
CONCENTRATION
Total LDL clearance and recycling of
cholesterol in homozygous FH (familial
hypercholesterolaemia)
Homozygous FH is, ostensibly, the simplest case to
analyse the impact of the LDL receptor pathways
on plasma LDL concentration. The reason is that, in
homozygousFH,thereisnouptakeviatheLDLreceptor
pathway and therefore clearance of LDL particles from
plasma occurs only through the non-speciﬁc pathways.
Perhaps counterintuitively, the total clearance of LDL
particles from plasma is not reduced in homozygous
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FH [9]. On the contrary, it is markedly elevated. Thus
Bilheimer et al. [9] demonstrated that the total mass
of LDL-cholesterol removed per day from plasma in
patients with FH was three times that in normal subjects.
In spite of that, there is no evidence that cholesterol
synthesis in patients with homozygous FH is reduced.
Accordingly, even though the uptake of cholesterol
into the hepatocyte of FH homozygotes via the non-
speciﬁc pathways occurs in amounts much larger than
normal, this does not appear to result in expansion of
the regulatory pool, which would trigger the down-
regulation of cholesterol synthesis.
If more cholesterol is entering the hepatocyte than
can be secreted in the bile, if the regulatory pool is
not expanded, and if cholesterol is not to accumulate
within the hepatocyte, there must be recycling of
cholesterol by the liver. The bulk of the cholesterol
that is taken up by the liver in the patients with
homozygous FH must be resecreted from the liver
either within apoB particles or via nascent HDL (high-
density lipoprotein) particles. Recycling is an obligatory
response to prevent accumulation of cholesterol within
the liver and almost certainly explains the increased
secretion of cholesterol-rich apoB particles in patients
with FH [4,9,11–14]. Recycling of cholesterol without
expansion of the regulatory pool would also explain why
cholesterol synthesis continues in the livers of patients
with homozygous FH.
In patients with normal LDL pathways,
how does clearance through speciﬁc and
non-speciﬁc pathways vary as plasma
levels of LDL increase?
The results in Figure 1 were derived from studies of
LDLturnoverinindividualswithnormalandmoderately
elevatedlevelsofLDL[15,16].Noneofthesesubjectshad
marked hypercholesterolaemia and therefore none had
FH or any other disorder producing marked impairment
ofclearancethroughtheLDLpathway.Totalclearanceof
LDL-apoB is equal to the sum of the uptakes through
the speciﬁc and the non-speciﬁc pathways. If the FCR
(fractional catabolic rate) for non-speciﬁc uptake of LDL
is 0.17 pools of LDL-apoB per day [9], the FCR for
speciﬁc uptake of LDL is equal to FCR total LDL
clearance−FCR non-speciﬁc LDL clearance, or FCR
speciﬁc LDL pathway=FCR total LDL clearance−0.17.
Figure 1 displays the total mass of LDL-apoB cleared
per day as well as the mass of LDL-apoB cleared through
the speciﬁc compared with the non-speciﬁc pathways
at increasing concentrations of LDL. The total mass of
LDL-cholesterol cleared per day is also illustrated as
well as the mass of LDL-cholesterol cleared through the
speciﬁc and non-speciﬁc pathways. The ﬁrst point to
note is the positive relationship between the total mass
of LDL-apoB cleared per day and the concentration
of LDL-apoB in plasma. For clearance to increase as
the concentration of LDL increases points to increased
production of LDL as the major determinant of the
concentration of LDL, an inference that is supported
by the formal calculations in these studies [15,16].
Secondly,themassofLDL-apoBclearedperdaythrough
the speciﬁc pathway varies little over the entire range of
concentrations of LDL-apoB. Thus, as the total mass
of LDL-cholesterol cleared per day increases, the
mass of LDL-cholesterol cleared through the spe-
ciﬁc pathway remains constant. Thirdly, because
the FCR of the non-speciﬁc pathway is con-
stant, the mass of LDL cleared via the non-
speciﬁc pathway increases linearly as plasma LDL
increases. The result is that the total mass of LDL-
apoB and LDL-cholesterol cleared per day equals the
constant amount taken up by the speciﬁc pathway
plus the constantly increasing amount taken up via the
non-speciﬁc pathways. These ﬁndings from the in vivo
turnover studies are supported by the in vitro studies of
Havekes and co-workers [17,18].
These ﬁndings challenge the LDL receptor paradigm
in three critical ways. First, even though the total mass
of cholesterol returned to the liver increases, there is no
down-regulation of the activity of the LDL receptor
pathway. On the contrary, the activity of the LDL
receptor pathway appears to be maintained as the plasma
concentration of LDL increases and as the total mass
ofcholesteroltransportedtotheliverincreases.Secondly,
cholesterolsynthesisissustainedandnotdown-regulated
as the LDL receptor paradigm would call for. Thirdly,
analogous to homozygous FH, intracellular cholesterol
homoeostasis will need to be maintained by secretion of
excess cholesterol from the liver.
Moreover, of the two mechanisms that govern the
concentration of LDL in plasma, these studies and
others [7–9,12] demonstrate that overproduction of LDL
particles is a much more common cause of elevated
LDL-cholesteroland-apoBthanimpairedclearance.This
ﬁnding is not the consequence of study selection, as we
will attempt to demonstrate in the next section.
LDL clearance compared with LDL
production as determinants of plasma
LDL
Table 1 demonstrates the effect on plasma LDL-apoB
concentration of progressive reduction in function of
the speciﬁc LDL pathway to zero in the face of normal
LDL production. The example is of a 70 kg male with a
plasmavolumeof3.5 litresandanLDLproductionrateof
10 mg · kg−1 of body weight · day−1. These calculations
illustrate that, if LDL production remains normal, there
must be profound impairment in the functioning of
the LDL pathway before LDL levels will be clearly
elevated. Even so, even when there is no transport
through the LDL pathway, LDL-apoB levels will be
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Figure 1 Results of LDL-apoB clearance and LDL clearance as the total and mass cleared through the speciﬁc and
non-speciﬁc pathways as the concentration of LDL-apoB increases in plasma
Note that the masses of apoB and cholesterol cleared through the speciﬁc LDL pathway do not vary signiﬁcantly as plasma LDL-apoB increases, whereas the clearance
through the non-speciﬁc pathways increases linearly. Data were taken from [15,16].
only modestly elevated. On the other hand, as shown
in Table 2, sequentially increasing the production of
LDL-apoB until it is double the normal levels will
produce more dramatic effects on plasma LDL-apoB
than decreasing the clearance of LDL. These calculations
conﬁrmtheconclusionsreachedpreviouslybyMeddings
and co-workers [19] and Bilheimer and co-workers
[9]. They also illustrate that increased production of
LDL is a major pathophysiological contributor to the
profoundlyelevatedlevelsofLDLinhomozygousFHas
indeedhasbeenrepeatedlydocumented[4,9,11–14].Most
important, as illustrated by the calculations in Table 3, it
is the combination of impaired clearance with increased
production that produces the most dramatic examples of
elevation of plasma LDL-apoB.
A NEW MODEL OF CHOLESTEROL
HOMOEOSTASIS WITHIN THE HEPATOCYTE
In this ﬁnal section, we will present our hypothesis
as to the different pathways that cholesterol can take
withinthehepatocyteandtheimplicationsforcholesterol
homoeostasis within the hepatocyte. First, we will
consider cholesterol that enters the cell directly into
the plasma membrane. Cholesterol within the plasma
membranemakesupthegreatestpoolofcholesterolwith-
in the cell. Once the capacity to sequester cholesterol
within the plasma membrane is exceeded, any excess
moveseithertoacceptorsoutsidethecellortositeswithin
the cell such as the ER (endoplasmic reticulum) and the
mitochondria. This sets off a broad set of regulatory
responses. Sequestration of SREBP (sterol-regulatory-
element-binding protein) within the ER results in down-
regulation of cholesterol and LDL receptor synthesis.
An even more immediate reaction may come from
increased synthesis of 27-hydroxycholesterol in the
mitochondria, which acutely reduces HMG-CoA (3-
hydroxy-3-methylglutaryl-CoA) reductase activity by
ubiquination of the enzyme [20]. It is also possible
that oxysterols generated in the mitochondria may
activate the LXRα (liver X receptor α) which, in turn,
may induce ABCA1 (ATP-binding-cassette transporter
A1) and IDOL (inducible degrader of the LDL
receptor)expressiontoup-regulatecholesterolefﬂuxand
LDL receptor degradation respectively [21]. Cholesterol
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Table 1 Effect of decreased clearance by LDL pathway with normal production of LDL
PR, production rate; NSC, non-speciﬁc LDL clearance; SC, speciﬁc LDL clearance.
NSC SC
PR (mg/day) FCR (pools/day) FCR (pools/day) FCR (mg/day) FCR (pools/day) FCR (mg/day) LDL-apoB pool (mg) LDL-apoB (mg/dl)
700 0.45 0.17 265 0.28 435 1559 45
700 0.42 0.17 283 0.25 417 1664 48
700 0.37 0.17 322 0.20 378 1894 54
700 0.32 0.17 372 0.15 328 2188 63
700 0.27 0.17 441 0.10 259 2594 74
700 0.22 0.17 541 0.05 159 3182 91
700 0.17 0.17 700 0.00 0 4177 118
Table 2 Effect of increased production of LDL on plasma LDL-apoB with normal LDL clearance
PR, production rate; NSC, non-speciﬁc LDL clearance; SC, speciﬁc LDL clearance.
NSC SC
PR (mg/day) FCR (pools/day) FCR (pools/day) FCR (mg/day) FCR (pools/day) FCR (mg/day) LDL-apoB pool (mg) LDL ApoB (mg/dl)
700 0.45 0.17 264 0.28 436 1553 45
800 0.37 0.17 364 0.20 436 2145 61
900 0.33 0.17 464 0.16 436 2729 78
1000 0.30 0.17 564 0.13 436 3317 95
1100 0.28 0.17 664 0.11 436 3906 112
1200 0.27 0.17 764 0.10 436 4494 128
1300 0.26 0.17 864 0.09 436 5082 145
1400 0.25 0.17 964 0.08 436 5671 162
Table 3 Effect of increased production of LDL on plasma LDL-apoB with reduced LDL clearance (33%)
PR, production rate; NSC, non-speciﬁc LDL clearance; SC, speciﬁc LDL clearance.
NSC SC
PR (mg/day) FCR (pools/day) FCR (pools/day) FCR (mg/day) FCR (pools/day) FCR (mass) LDL-apoB pool (mg) LDL ApoB (mg/dl)
700 0.29 0.17 410 0.12 290 2411 69
800 0.27 0.17 510 0.10 290 2941 86
900 0.25 0.17 610 0.08 290 3588 103
1000 0.24 0.17 710 0.07 290 4177 119
1100 0.23 0.17 810 0.06 290 4764 136
1200 0.22 0.17 910 0.05 290 5353 153
1300 0.22 0.17 1010 0.05 290 5941 170
1400 0.21 0.17 1110 0.04 290 6529 187
in the ER can also be esteriﬁed by ACAT (acyl-
CoA:cholesterol acyltransferase) and then either stored
within the cytoplasm or secreted from the cell within
an apoB lipoprotein particle. In this sequence, all of
the appropriate and known regulatory responses are
triggered before the cholesterol is esteriﬁed.
On the basis of the observations we have presented
in the present article, we hypothesize that an alternative
sequence is possible, namely that the cholesterol within
an LDL particle within a lysosome is delivered directly
to ACAT and the bulk of the cholesterol within the
particle is esteriﬁed before there is a signiﬁcant increase
in the concentration of cholesterol at the ER or the
mitochondria. The consequence is that cholesterol taken
up within the LDL particle can be resecreted without
a signiﬁcant change in the synthesis of LDL receptors
or cholesterol. This would explain the shunting and
recyclingofcholesterolthatwasﬁrstobservedinFHbut,
as we have shown, is also present in many, if not most,
subjects with elevated LDL. We suggest that recycling of
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cholesterol within the hepatocyte is the key process that
permits continued clearance of LDL through the LDL
receptorandpersistentcholesterolsynthesisinthefaceof
increased delivery of cholesterol to the liver. We suspect
that the course followed by other lipoprotein particles,
such as chylomicron remnants, may correspond more
closely to the ﬁrst route we have outlined rather than the
second.
SUMMARY
In summary, the apoB paradigm differs from the LDL
receptor paradigm in two critical regards. First, the apoB
paradigm reveals that the concentration of LDL particles
in plasma is determined not only by the rate at which
they are cleared, but also, and generally even more
importantly, by the rate at which they are produced.
Secondly, in the apoB paradigm, cholesterol synthesis is
not constrained as it is in the LDL receptor paradigm.
The LDL receptor paradigm demands tight regulation
of cholesterol synthesis and preserves the equilibrium of
the mass of cholesterol within the organism, whereas the
apoB paradigm allows for disequilibrium and expansion
of the mass of cholesterol within the organism. The
disequilibrium that is a hallmark of the apoB paradigm is
much more consistent with the pathophysiology of the
major apoB atherogenic dyslipoproteinaemias than is the
LDL receptor paradigm.
The reorientation in our understanding called for by
the apoB paradigm opens new research and therapeutic
opportunities. Different lipoprotein particles are taken
up by the hepatocyte by different mechanisms. This
almost certainly results in different delivery sites within
the hepatocyte. These differences are important because
they may determine whether the cholesterol within a
lipoprotein particle is delivered to the regulatory or to
the shunt pathways. With regard to treatment, therapy
for elevated LDL presently focuses on increasing the
activity of the LDL receptor pathway. The value of
this approach is enormous, but many patients remain
undertreated.TheapoBparadigmpointstoproductionas
themajormechanismgoverningtheplasmaconcentration
of LDL. Therefore therapeutic opportunities to diminish
apoB secretion should be pursued vigorously [22].
Decreasing VLDL secretion will not necessarily increase
total cholesterol mass within the hepatocyte as it may
allow more time for equilibration with the regulatory
pools and therefore decreased synthesis and uptake.
Obviously much work will be necessary to determine
the validity of these concepts. Nevertheless, the apoB
paradigm appears to provide a more explanatory model
of the regulation of plasma LDL and cholesterol
homoeostasis in the hepatocyte than the LDL receptor
paradigm.
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